News about
rnatics

24.05.25

NUCLEATE Cluster of Excellence: Unlocking the Potential of Nucleic Acids

The newly formed NUCLEATE Cluster of Excellence focuses entirely on nucleic acids and their therapeutic potential.

13.02.25

RNATICS welcomes Prof. Dr. Thomas Thum to its board

Prof. Dr. Thomas Thum joins RNATICS' board to advance its clinical programs and expand the targeted therapy portfolio with his strategic insight and track record.

8.10.24

2024 Nobel prize in Medicine awarded to microRNA

2024 Nobel prize in Medicine awarded to microRNA - the target of RNATICS’ first-in-class inhalation therapeutic RCS-21.

Load More ...

15.11.23

RNATICS announces distinguished Advisory Board

Prestigious advisory board with highly experienced members in the nucleic acid therapeutics field will be instrumental in advancing RNATICS' innovative therapies to improve human health.

8.08.23

Underlying science of RNATICS’ technology published in Nature Communications

First-in-class mechanism to efficiently target RNA therapeutics to alveolar macrophages and its therapeutic potential described.

14.09.22

RNATICS receives prestigious Pharma Trend Image & Innovation Award 2022 for novel RNA therapeutic against COVID-19

RNATICS awarded for breakthrough innovation in RNA therapeutics for its lead programme RCS-21.

9.05.22

RNATICS technology wins Innovationspreis 2022 of BIO Deutschland

RNATICS technology selected as one of three outstanding technologies in Germany in 2022.

17.03.22

RNATICS featured in national newspaper

rnatics has been covered in the national newspaper Süddeutsche Zeitung as one of three biotech start-ups in Munich working on RNA therapeutics.

13.01.22

RNATICS granted € 7 million for the clinical development of a new COVID-19 drug

Federal Ministry of Education and Research funds clinical testing of RCS-21.

13.01.22

Report from the Technical University of Munich on rnatics as one of its most promising startups

A spray to protect against lung damage from Covid-19